Automatic Data Processing Inc vs BIO-TECHNE Corp — how do they compare? Automatic Data Processing Inc trades at $271.34 (market cap $108.72B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Automatic Data Processing Inc is far larger — about 9.7× BIO-TECHNE Corp's market cap, and Automatic Data Processing Inc pays the higher dividend (2.48%). Which is the better fit depends on your goals.
| ADP | TECH | |
|---|---|---|
Market Cap | $108.72B | $11.24B |
Sector | Industrials | Health |
52-Week High | $309.03 | $72.29 |
52-Week Low | $188.79 | $43.31 |
Enterprise Value | $109.76B | $11.32B |
Dividend Yield | 2.48% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
ADP trades at $271.32, down 0.8% for the day, with strong technical momentum showing bullish moving averages and key support at $269. The company demonstrates robust fundamentals with consistent earnings beats, 20.11% net margins, and 72.24% ROE. Recent Q4 2026 results showed 7% revenue growth and 17% EPS growth, driving positive analyst sentiment despite elevated valuation multiples.
Outlook remains positive with a $280.50 consensus price target offering 3.4% upside potential. Key opportunities include margin expansion and dividend stability, while risks center on high valuation sensitivity and labor market volatility affecting ADP's payroll processing business. The stock presents a quality growth opportunity with disciplined risk management required.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →